Overview
Motohiro Izumi practices practicing medicine in Wakayama, Japan.
Izumi is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), PIK3CA-Related Overgrowth Spectrum, and Lung Adenocarcinoma.
They are actively involved in clinical research, co-authoring 19 peer reviewed articles.
Locations
Sakai, Japan
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Motohiro Izumi
Is Motohiro Izumi a top-rated expert for Lung Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Motohiro Izumi is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Motohiro Izumi participate in research or clinical trials?
Yes. Motohiro Izumi has published 19 articles and abstracts on conditions like Lung Cancer. You can view a list of Motohiro Izumi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Lung CancerIzumi isAdvanced. Learn about Lung Cancer.
- Experienced
- DysarthriaIzumi isExperienced. Learn about Dysarthria.
- Lung AdenocarcinomaIzumi isExperienced. Learn about Lung Adenocarcinoma.
- Non-Small Cell Lung Cancer (NSCLC)
- PIK3CA-Related Overgrowth Spectrum